Dr. David Russler-Germain, M.D., Ph.D.
Claim this profileWashington University School of Medicine
Area of expertise
Lymphoma
David Russler-Germain, M.D., Ph.D. has run 3 trials for Lymphoma. Some of their research focus areas include:
Follicular Lymphoma
David Russler-Germain, M.D., Ph.D. has run 3 trials for Follicular Lymphoma. Some of their research focus areas include:
Affiliated Hospitals
Washington University School Of Medicine
Clinical Trials David Russler-Germain, M.D., Ph.D. is currently running
Mosunetuzumab
for Aggressive B-Cell Lymphoma
This phase 1 pilot study examines the feasibility and safety of mosunetuzumab after autologous stem cell transplant for patients with aggressive B cell lymphomas. Mosunetuzumab is an antibody that has been engineered to attach to two target cells in the immune system: T cells that normally perform tasks like killing virus-infected cells, and cancerous B cells. Mosunetuzumab has been designed to direct these T cells to kill the cancerous B cells instead.
Recruiting
2 awards
Phase 1
Thiotepa + Stem Cell Transplant
for Lymphoma
A serious consequence of systemic diffuse large B-cell lymphoma (DLBCL) is secondary central nervous system (CNS) relapse, which occurs in approximately 5% of all patients. Many CNS relapses occur within the first year after completion of frontline treatment and are associated with significantly increased mortality; thus, it is important to tailor frontline treatment to provide prophylaxis against CNS relapse in those patients who are determined to be high-risk. Autologous stem cell transplantation (ASCT) is standard of care for patients with DLBCL who relapse one year or more after first remission, and it has been shown to improve progression-free survival for patients with primary CNS lymphoma. The four-drug BEAM regimen (carmustine, etoposide, cytarabine, and melphalan) is the preferred conditioning regimen for DLBCL patients undergoing ASCT; however, patients with primary CNS lymphoma receive thiotepa plus carmustine as their conditioning regimen due to its better CNS penetration. This study tests the hypothesis that consolidation thiotepa/carmustine ASCT in first complete remission will reduce the risk of CNS relapse in transplant-eligible patients with DLBCL with no prior CNS disease at high risk of secondary CNS recurrence.
Recruiting
1 award
Phase 2
3 criteria
More about David Russler-Germain, M.D., Ph.D.
Clinical Trial Related
3 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments David Russler-Germain, M.D., Ph.D. has experience with
- Mosunetuzumab
- Polatuzumab Vedotin
- DHAX
- ICE
- Autologous Stem Cell Transplant
- Carmustine
Breakdown of trials David Russler-Germain, M.D., Ph.D. has run
Lymphoma
Follicular Lymphoma
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Diffuse Large B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David Russler-Germain, M.D., Ph.D. specialize in?
David Russler-Germain, M.D., Ph.D. focuses on Lymphoma and Follicular Lymphoma. In particular, much of their work with Lymphoma has involved Stage III patients, or patients who are Stage IV.
Is David Russler-Germain, M.D., Ph.D. currently recruiting for clinical trials?
Yes, David Russler-Germain, M.D., Ph.D. is currently recruiting for 2 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that David Russler-Germain, M.D., Ph.D. has studied deeply?
Yes, David Russler-Germain, M.D., Ph.D. has studied treatments such as Mosunetuzumab, Polatuzumab vedotin, DHAX.
What is the best way to schedule an appointment with David Russler-Germain, M.D., Ph.D.?
Apply for one of the trials that David Russler-Germain, M.D., Ph.D. is conducting.
What is the office address of David Russler-Germain, M.D., Ph.D.?
The office of David Russler-Germain, M.D., Ph.D. is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.